ARTICLE | Emerging Company Profile

Rome: tackling repeat DNA for cancer, autoimmunity

Rome launches with $50M series A round to leverage repeat biology

April 29, 2020 11:48 PM UTC

GV-incubated Rome joins a growing cadre of companies targeting repeat biology, with plans to suppress repeat DNA-induced innate immune responses to treat autoimmune disorders and activate the same pathways for cancer.

Rome Therapeutics Inc. launched Monday with a $50 million series A round co-led by GV and Arch Venture Partners; Partners Innovation Fund also participated...